INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 21 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $300 | +1.0% | 3,000 | 0.0% | 0.01% | -6.7% |
| Q1 2023 | $297 | +1.0% | 3,000 | 0.0% | 0.02% | -6.2% |
| Q4 2022 | $294 | -100.0% | 3,000 | -76.9% | 0.02% | -77.1% |
| Q3 2022 | $1,251,000 | +0.2% | 13,000 | 0.0% | 0.07% | +2.9% |
| Q2 2022 | $1,248,000 | +5.1% | 13,000 | 0.0% | 0.07% | +25.9% |
| Q1 2022 | $1,188,000 | -2.9% | 13,000 | 0.0% | 0.05% | +1.9% |
| Q4 2021 | $1,224,000 | +5.0% | 13,000 | 0.0% | 0.05% | -3.6% |
| Q3 2021 | $1,166,000 | +0.1% | 13,000 | 0.0% | 0.06% | 0.0% |
| Q2 2021 | $1,165,000 | +10.1% | 13,000 | 0.0% | 0.06% | -6.8% |
| Q1 2021 | $1,058,000 | +5.6% | 13,000 | 0.0% | 0.06% | -33.0% |
| Q4 2020 | $1,002,000 | +315.8% | 13,000 | +333.3% | 0.09% | +282.6% |
| Q3 2020 | $241,000 | +6.6% | 3,000 | 0.0% | 0.02% | +9.5% |
| Q2 2020 | $226,000 | -5.8% | 3,000 | 0.0% | 0.02% | -27.6% |
| Q1 2020 | $240,000 | -20.5% | 3,000 | 0.0% | 0.03% | +7.4% |
| Q4 2019 | $302,000 | +17.1% | 3,000 | 0.0% | 0.03% | +8.0% |
| Q3 2019 | $258,000 | -3.4% | 3,000 | 0.0% | 0.02% | -7.4% |
| Q2 2019 | $267,000 | -10.1% | 3,000 | 0.0% | 0.03% | -15.6% |
| Q1 2019 | $297,000 | +7.6% | 3,000 | 0.0% | 0.03% | -8.6% |
| Q4 2018 | $276,000 | -8.9% | 3,000 | 0.0% | 0.04% | +2.9% |
| Q3 2018 | $303,000 | +15.2% | 3,000 | 0.0% | 0.03% | +3.0% |
| Q2 2018 | $263,000 | – | 3,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|